The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC
Zhonglin Hao, MD, PhD, University of Kentucky, Lexington, KY, presents preliminary findings from an ongoing Phase I dose-escalation study (NCT05680922) evaluating LB2102, a DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). LB2102 demonstrated consistent CAR-T expansion and encouraging anti-tumour activity at higher dose levels, with a manageable safety profile including no dose-limiting toxicities and resolvable cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome cases. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
